North America and Europe Women’s Health Market Size, Share, and Trends Analysis Report – Industry Overview and Forecast to 2032

North America and Europe Women’s Health Market Size

• The North America and Europe women’s health market size was valued at USD 9.84 billion in 2024 and is expected to reach USD 18.23 billion by 2032, at a CAGR of 8.0% during the forecast period
• The market growth is largely fueled by increasing awareness, improved healthcare infrastructure, and rising investments in women-centric medical research, leading to the development of innovative treatments across reproductive, postmenopausal, and hormonal health
• Furthermore, growing demand for early diagnosis, personalized care, and preventive healthcare measures is reinforcing the need for specialized women’s health solutions. These converging factors are accelerating innovation and accessibility, thereby significantly boosting the industry’s growth

North America and Europe Women’s Health Market Analysis

• Women’s health, encompassing services and products addressing reproductive, hormonal, and general wellness needs, is becoming an increasingly prioritized sector in both North America and Europe due to shifting demographics, increased awareness, and advancements in targeted medical technologies
• The rising demand for women’s health solutions is primarily fueled by growing incidences of chronic and reproductive health conditions, expanding access to healthcare, and proactive government and private sector initiatives aimed at improving women’s health outcomes
• North America dominated the women’s health market with the largest revenue share of 42% in 2024, characterized by high healthcare expenditure, favorable reimbursement policies, and a strong focus on research and development, particularly in areas such as fertility, menopause, and breast health
• Europe is expected to witness robust growth in the women’s health market during the forecast period, driven by increasing public health awareness, supportive healthcare regulations, and growing investments in personalized and preventive women’s healthcare services
• The postmenopausal syndrome segment dominated the women’s health market with a market share of 40.2% in 2024, propelled by a rising aging female population and growing availability of hormone replacement therapies and targeted treatments

Report Scope and North America and Europe Women’s Health Market Segmentation

North America and Europe Women’s Health Market Trends

Personalized and Preventive Care Through Digital Health Innovations

• A significant and accelerating trend in the North America and Europe women’s health market is the rise of personalized and preventive care enabled by digital health technologies, such as mobile health (mHealth) apps, telemedicine platforms, and wearable devices. These tools are transforming how women monitor, manage, and engage with their health
  • For instance, apps such as Clue and Flo offer AI-powered menstrual and fertility tracking, enabling women to anticipate hormonal changes and manage reproductive health more effectively. Meanwhile, wearables such as the Ava bracelet provide real-time data on fertility indicators, empowering users with predictive insights
• Integration with digital platforms allows for remote consultation, early detection, and tailored health interventions, particularly for conditions such as endometriosis, PCOS, and menopause-related issues. AI algorithms analyze user-specific health data to deliver customized recommendations, alerts, and follow-ups, promoting proactive health management
• This shift is also enabling healthcare professionals to deliver more individualized care plans, especially in reproductive, hormonal, and postmenopausal care, enhancing both patient engagement and clinical outcomes. In North America and Europe, the adoption of telehealth solutions surged post-pandemic, normalizing virtual care delivery in women’s health
• Consequently, companies such as Natural Cycles and Bayer are leveraging digital platforms to introduce hormone-free contraception and support adherence to treatment regimens. Health systems and startups asuch as are focusing on user-friendly, privacy-compliant solutions to expand access and improve long-term women’s health outcomes
• The growing preference for accessible, data-driven, and customized healthcare is shaping a new standard of care in the women’s health market, reinforcing digital health as a cornerstone of innovation in both preventive and therapeutic services

North America and Europe Women’s Health Market Dynamics

Driver

Rising Health Awareness and Supportive Policy Environment

• The increasing awareness of women-specific health issues, combined with growing advocacy for gender-focused research and services, is a major driver of the women’s health market in North America and Europe
  • For instance, governmental initiatives such as the NIH’s Women’s Health Research Program in the U.S. and the EU’s Horizon Europe health cluster are expanding funding for research and access to care
• These efforts, along with public health campaigns, are pushing forward early diagnosis, regular screening, and preventive health checkups
• In addition, the rising incidence of conditions such as osteoporosis, breast cancer, and endometriosis, as well as increasing demand for fertility treatments, are prompting the development of advanced diagnostics, hormone therapies, and digital interventions
• The broadening insurance coverage and reimbursement policies across both regions also play a key role in making these health solutions more accessible. Combined with strong healthcare infrastructure and rising investments in FemTech, these factors are significantly contributing to market expansion

Restraint/Challenge

Regulatory Complexities and Cultural Barriers in Access

• Despite advancements, the market faces challenges related to regulatory heterogeneity, data privacy concerns, and persistent cultural stigmas around reproductive and sexual health in certain populations
  • For instance, navigating the regulatory approval process for hormone therapies, contraceptives, and digital health applications varies significantly between countries, often slowing product launches and market entry
• In addition, privacy concerns around sensitive health data collected by apps and wearables, particularly under regulations such as GDPR and HIPAA, can deter usage and adoption unless fully addressed
• Cultural and socio-economic factors continue to limit access to comprehensive women’s health services in certain rural or underserved communities, creating disparities in care. While North America and Europe lead in innovation, ensuring equitable distribution of care and overcoming stigma through education and policy reform remain key challenges
• Overcoming these barriers through streamlined regulations, inclusive education campaigns, and culturally sensitive healthcare delivery will be essential for long-term, equitable market growth

North America and Europe Women’s Health Market Scope

The market is segmented on the basis of treatment, indication, delivery mode, drug type, care type, end user, and distribution channel.

• By Treatment

On the basis of treatment, the North America and Europe women’s health market is segmented into drugs and devices. The drugs segment dominated the market with the largest revenue share in 2024, driven by the extensive use of hormone replacement therapies (HRT), osteoporosis medications, and therapies for managing post-menopausal symptoms. The rising incidence of hormonal imbalance, aging population, and increasing awareness regarding treatment options are contributing to the dominance of this segment.

The devices segment is expected to witness significant growth from 2025 to 2032, fueled by the adoption of diagnostic tools, contraceptive devices, and wearable technologies. Advancements in non-invasive monitoring and growing consumer demand for self-care solutions are accelerating the use of women’s health-related devices in both clinical and home settings.

• By Indication

On the basis of indication, the North America and Europe women’s health market is segmented into cancer, reproductive health, urological disorders, hypothyroidism, post-menopausal syndrome, and others. The post-menopausal syndrome segment dominated the market with the largest market revenue share of 40.2% in 2024, driven by the increasing aging female population and growing demand for therapies addressing symptoms such as hot flashes, osteoporosis, night sweats, and mood disorders. The availability of innovative HRT solutions and strong support from healthcare providers are key drivers for this segment.

The reproductive health segment is projected to grow steadily during the forecast period, supported by rising infertility rates, increasing awareness of menstrual health, and growing demand for assisted reproductive technologies (ART).

• By Delivery Mode

On the basis of delivery mode, the North America and Europe women’s health market is bifurcated into prescription and over-the-counter (OTC). The prescription segment held the largest share of the market in 2024, driven by the widespread use of physician-prescribed treatments for hormonal, reproductive, and menopausal conditions that require continuous monitoring and medical oversight.

The OTC segment is expected to grow at a strong pace during forecast period, supported by the increasing availability of non-prescription products for general wellness, menstrual relief, and menopausal symptom management, especially among health-conscious consumers seeking convenient access.

• By Drug Type

On the basis of drug type, the North America and Europe women’s health market is segmented into branded and generic. The branded segment dominated the market in 2024 due to high brand trust, physician preference, and effective marketing of specialized treatments for menopause, fertility, and chronic hormonal disorders.

The generic segment is projected to register the fastest growth from 2025 to 2032, driven by cost efficiency, favorable reimbursement policies, and the expiration of patents on major branded drugs, allowing more affordable access to treatment.

• By Care Type

On the basis of care type, the North America and Europe women’s health market is segmented into general healthcare & wellness, pregnancy & nursing care, pelvic & uterine healthcare, and others. The general healthcare & wellness segment led the market in 2024, fueled by growing emphasis on preventive care, chronic disease management, and regular health screenings. Increasing awareness of lifestyle-related health issues among women is contributing to demand for general wellness solutions.

The pelvic & uterine healthcare segment is expected to witness robust growth during the forecast period, driven by increasing diagnosis and treatment of fibroids, endometriosis, and uterine disorders, particularly among peri- and post-menopausal women.

• By End User

On the basis of end user, the North America and Europe women’s health market is segmented into hospitals and clinics, gynecology centers, homecare settings, research institutes, and others. Hospitals and clinics dominated the market with the largest revenue share in 2024, owing to the availability of comprehensive diagnostic and treatment services, specialist gynecological care, and established infrastructure. These settings are the primary point of access for HRT and advanced reproductive treatments.

Homecare settings are expected to witness the fastest growth during the forecast period, supported by rising adoption of digital health technologies, increasing preference for at-home health monitoring, and growing availability of remote consultations and personalized care plans.

• By Distribution Channel

On the basis of distribution channel, the North America and Europe women’s health market is segmented into direct tenders, retail sales, online sales, and others. Retail sales held the largest market share in 2024, supported by strong distribution networks, easy accessibility of prescription and OTC products, and consumer reliance on pharmacy-based consultations.

Online sales are projected to experience the highest growth rate from 2025 to 2032, fueled by the increasing popularity of e-commerce platforms, demand for privacy in purchasing women’s health products, and the rise of digital-first healthcare brands offering direct-to-consumer solutions.

North America and Europe Women’s Health Market Regional Analysis

• North America dominated the women’s health market with the largest revenue share of 42% in 2024, characterized by high healthcare expenditure, favorable reimbursement policies, and a strong focus on research and development, particularly in areas such as fertility, menopause, and breast health
• Women in the region increasingly seek advanced care for post-menopausal symptoms, fertility issues, and hormonal imbalances, supported by strong insurance coverage and a proactive approach to preventive health
• This dominance is further reinforced by the presence of leading pharmaceutical companies, a robust regulatory framework, and widespread access to gynecology and specialty care services, positioning North America at the forefront of women’s health innovation and service delivery

U.S. Women’s Health Market Insight

The U.S. women’s health market captured the largest revenue share in 2024 within North America and Europe, driven by the country’s advanced healthcare infrastructure, strong focus on reproductive and hormonal health, and widespread access to specialized treatments. Increased public awareness, supportive government initiatives, and the growing adoption of digital health solutions are significantly contributing to the market's expansion. Moreover, rising investments in research and innovation in areas such as menopause, fertility, and chronic conditions are accelerating the industry’s overall growth.

France Women’s Health Market Insight

The France women’s health market is projected to grow at the fastest CAGR throughout the forecast period, fueled by expanding national health programs, increased awareness of menopausal and gynecological disorders, and improved access to preventive care services. The growing adoption of telehealth and diagnostics, coupled with supportive regulatory policies, is enhancing treatment accessibility. Moreover, ongoing government efforts to modernize women’s health infrastructure are playing a pivotal role in shaping the future of care delivery across the country.

Canada Women’s Health Market Insight

The Canada women’s health market is witnessing strong growth owing to rising investments in gender-specific care, widespread use of digital health platforms, and the integration of holistic wellness services. The country’s universal healthcare system, combined with increasing public awareness campaigns around reproductive and post-menopausal health, is encouraging timely screening and early intervention. In addition, expanding access to telemedicine and fertility services is driving demand across both urban and rural regions.

Germany Women’s Health Market Insight

The Germany women’s health market is experiencing consistent growth, supported by a well-established healthcare system, rising health consciousness, and increasing demand for personalized treatment options. Enhanced focus on preventive care, rising utilization of hormone replacement therapies, and innovations in fertility treatments are shaping the country’s women’s health landscape. The incorporation of digital diagnostics and AI-powered platforms is also streamlining care and boosting patient engagement.

U.K. Women’s Health Market Insight

The U.K. women’s health market is gaining momentum due to growing awareness of female-specific health conditions, increasing investment in healthcare technology, and expanding access to specialist services. The national rollout of women-focused programs addressing menopause, menstrual health, and fertility is contributing significantly to market growth. In addition, the integration of virtual care models and the emphasis on patient-centric approaches are supporting the delivery of more efficient and accessible care.

North America and Europe Women’s Health Market Share

The North America and Europe Women’s Health industry is primarily led by well-established companies, including:

• AbbVie Inc. (U.S.)
• Bayer AG (Germany)
• Organon & Co. (U.S.)
• Pfizer Inc. (U.S.)
• Novo Nordisk A/S (Denmark)
• Hologic, Inc. (U.S.)
• GE HealthCare Technologies Inc. (U.S.)
• Merck KGaA (Germany)
• Theramex HQ UK Limited (U.K.)
• Gedeon Richter Plc. (Hungary)
• Myovant Sciences GmbH (Switzerland)
• Amgen Inc. (U.S.)
• Mithra Pharmaceuticals S.A. (Belgium)
• Teva Pharmaceutical Industries Ltd. (Israel)
• Biogen Inc. (U.S.)
• Lilly (U.S.)
• Ferring B.V. (Switzerland)
• Agile Therapeutics, Inc. (U.S.)
• ObsEva SA (Switzerland)
• Exeltis Healthcare, S.L. (Spain)

What are the Recent Developments in North America and Europe Women’s Health Market?

• In April 2024, Organon, a global healthcare company focused on women’s health, launched a cross-border awareness campaign across the U.S., U.K., and Germany to promote education around menopause management. This initiative underscores the company’s dedication to expanding access to information and non-hormonal treatment options, aiming to empower women and healthcare providers in addressing post-menopausal challenges through evidence-based solutions
• In March 2024, Hologic, Inc., a U.S.-based medical technology company, expanded its Breast Health solutions portfolio by introducing next-generation imaging systems across diagnostic centers in Canada and France. This advancement enhances early detection and diagnostic accuracy, reaffirming Hologic’s commitment to reducing breast cancer mortality through advanced technology and increasing access to life-saving screening programs across developed healthcare systems
• In March 2024, Bayer AG, headquartered in Germany, announced the expansion of its clinical trial network focused on endometriosis and uterine fibroids in North America and Europe. The initiative includes collaboration with leading academic institutions in the U.S. and U.K., reflecting Bayer’s strategic investment in innovation and personalized treatments for chronic gynecological conditions affecting millions of women globally
• In February 2024, Theramex, a women’s health-focused pharmaceutical company based in London, entered into a licensing agreement to commercialize a new hormone-free contraceptive in key European markets including France, Spain, and Italy. This move aligns with the rising demand for safe, non-hormonal birth control options and reflects Theramex’s ongoing mission to offer diversified solutions tailored to women’s evolving health needs
• In January 2024, Maven Clinic, a leading U.S.-based virtual care platform for women and families, announced its expansion into Germany and the U.K., offering digital access to fertility, maternity, and menopause care services. The move is part of Maven’s broader international strategy to make personalized, tech-enabled women’s healthcare more accessible, convenient, and inclusive across both North America and Europe

SKU-70483